CG Oncology (NASDAQ:CGON) Research Coverage Started at UBS Group

UBS Group started coverage on shares of CG Oncology (NASDAQ:CGON) in a research note published on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $60.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Roth Capital raised CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Tuesday, September 17th. Royal Bank of Canada began coverage on shares of CG Oncology in a research note on Monday, September 23rd. They issued an “outperform” rating and a $66.00 price objective for the company. Bank of America restated a “buy” rating and issued a $65.00 target price on shares of CG Oncology in a report on Tuesday, October 8th. Finally, Roth Mkm started coverage on shares of CG Oncology in a report on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target for the company. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $63.88.

CG Oncology Price Performance

CGON stock opened at $36.38 on Thursday. The company’s fifty day moving average price is $36.64 and its 200-day moving average price is $34.78. CG Oncology has a one year low of $25.77 and a one year high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The company had revenue of $0.11 million for the quarter. As a group, analysts anticipate that CG Oncology will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the completion of the transaction, the director now owns 586,982 shares in the company, valued at $20,755,683.52. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Institutional Trading of CG Oncology

Several institutional investors and hedge funds have recently made changes to their positions in CGON. Decheng Capital LLC purchased a new position in CG Oncology in the 1st quarter worth about $239,642,000. Vanguard Group Inc. bought a new stake in shares of CG Oncology during the first quarter valued at approximately $97,678,000. BVF Inc. IL purchased a new stake in shares of CG Oncology in the first quarter valued at approximately $82,716,000. Yu Fan bought a new position in CG Oncology in the second quarter worth approximately $49,828,000. Finally, Janus Henderson Group PLC purchased a new position in CG Oncology during the 1st quarter worth $66,757,000. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.